An interventional study of Trehalose Powder Air-Polishing and Glycine Powder Air-Polishing in Peri-implant Mucositis, sponsored by University of Pavia. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by University of Pavia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Mucositis with a site in Italy — 3 open to participants now, 3 under way, none of them phase 3. Mucositis · Italy.
Among the 29 studies in Mucositis with a site in Italy, this one is the 14th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2025, is one of 19 with no phase, and was the 28th registered.
265 studies on the registry are indexed under Mucositis; 34 are open to participants now.
Browse Mucositis studies →3 of the 29 studies in Mucositis with a site in Italy are open now. Recruiting first, the newest first:
Koite Health Oy · Sites in Italy
Ages 18+
University of Catania · Sites in Italy
Ages 18–75 · Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 21 Mucositis studies recruiting now, 13 (62%) set no upper age limit and 7 (33%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 2 · Phase 4 1
First in 2006; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 40 is below the median of 45 across 215 interventional studies indexed under Mucositis.
Median enrollment 52 across the 23 interventional studies, 78 across the 6 observational. Of the 22 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 29 have an industry lead sponsor. The 10 most frequent:
University of Pavia is the lead sponsor of 144 studies on the registry; 38 are open to participants now.
University of Pavia has 7 studies filed under Mucositis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Mucositis with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized controlled clinical trial investigates the effectiveness of trehalose powder compared to glycine powder when used in air-polishing during supportive therapy for peri-implant mucositis, a reversible inflammatory condition affecting the soft tissues around dental implants.
A total of 40 adult patients with peri-implant mucositis will be enrolled and randomly assigned to receive non-surgical periodontal therapy combined with air-polishing using either trehalose powder (test group) or glycine powder (control group). Clinical parameters will be evaluated at baseline, 1 month, 3 months, and 6 months. These include Plaque Index (PI), Bleeding on Probing (BoP), Probing Pocket Depth (PPD), and Bleeding Score (BS), in order to assess plaque accumulation, inflammation, and bleeding.
The primary objective is to compare the reduction in plaque levels between the two groups over the study period. Secondary outcomes include evaluation of changes in gingival inflammation and probing depths, as well as assessment of implant surface integrity through in vitro scanning electron microscopy (SEM) after treatment.
The aim of the study is to determine whether trehalose powder offers improved clinical outcomes and greater implant surface preservation compared to glycine powder in the non-surgical management of peri-implant mucositis.
Peri-implant mucositis is a reversible inflammatory condition affecting the soft tissues surrounding dental implants and represents an early stage in the progression toward peri-implantitis if left untreated. Mechanical debridement combined with minimally invasive biofilm removal strategies has become the cornerstone of current supportive therapy. Among the available options, air-polishing powders have shown favorable outcomes in biofilm disruption without damaging implant surfaces or peri-implant tissues.
This randomized controlled clinical trial aims to compare the clinical efficacy and safety of trehalose powder versus glycine powder in supportive treatment of peri-implant mucositis. Trehalose is a disaccharide with documented antioxidant, anti-inflammatory, and cytoprotective properties, potentially enhancing tissue healing. Glycine, an amino acid widely used in air-polishing, has proven effective in biofilm removal with high biocompatibility and minimal abrasiveness.
Forty patients diagnosed with peri-implant mucositis will be randomly assigned to two groups: a test group receiving supportive periodontal therapy plus air-polishing with trehalose powder, and a control group receiving the same protocol with glycine powder. Clinical outcomes, including plaque accumulation, bleeding on probing, probing pocket depth, and bleeding score, will be assessed at baseline and at 1, 3, and 6 months. In addition, in vitro scanning electron microscopy (SEM) will evaluate implant surface integrity after treatment.
The study is designed to provide new clinical and morphological evidence on the potential benefits of trehalose in peri-implant maintenance protocols and to clarify whether it may represent a valid alternative to glycine for long-term implant health.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive supragingival and subgingival air-polishing with trehalose powder in combination with supportive peri-implant therapy, including manual and ultrasonic debridement, at baseline, 1, 3, and 6 months. Clinical parameters evaluated include Plaque Index (PI), Bleeding on Probing (BoP), Probing Pocket Depth (PPD), and Bleeding Score (BS). In vitro scanning electron microscopy (SEM) is used to assess potential alterations on the implant surface.
Device: Trehalose Powder Air-Polishing
Patients receive supragingival and subgingival air-polishing with glycine powder in combination with supportive peri-implant therapy, including manual and ultrasonic debridement, at the same timepoints (baseline, 1, 3, and 6 months). The same clinical parameters (PI, BoP, PPD, BS) are recorded. Implant surface integrity is assessed post-treatment by scanning electron microscopy (SEM).
Device: Glycine Powder Air-Polishing
Air-polishing procedure using trehalose-based powder (particle size \<65 µm, low abrasiveness) applied supra- and subgingivally with a professional air-polishing device in patients diagnosed with peri-implant mucositis. The intervention is combined with non-surgical debridement using manual curettes and ultrasonic scalers. The procedure is performed at baseline (T0), and repeated at 1 month (T1), 3 months (T2), and 6 months (T3). Clinical outcomes assessed include Plaque Index (PI), Bleeding on Probing (BoP), Probing Pocket Depth (PPD), and Bleeding Score (BS). Implant surfaces are also evaluated in vitro using scanning electron microscopy (SEM) to assess any surface alterations after powder application.
Air-polishing procedure using glycine-based powder (particle size \~25 µm, amino acid composition) applied supra- and subgingivally with a professional air-polishing device in patients with peri-implant mucositis. This treatment is combined with standard non-surgical supportive peri-implant therapy involving manual and ultrasonic debridement. The procedure is performed at baseline (T0), and repeated at 1 month (T1), 3 months (T2), and 6 months (T3). The intervention aims to reduce plaque accumulation and inflammation. Clinical parameters recorded include PI, BoP, PPD, and BS. Implant surfaces are also assessed in vitro via SEM to compare the effects of glycine versus trehalose on implant surface integrity.
Change in plaque accumulation assessed by Plaque Index (PI)
The Plaque Index (PI) will be used to assess the amount of bacterial plaque on peri-implant surfaces in patients with peri-implant mucositis. The PI will be recorded on four surfaces per implant (mesial, distal, buccal, and palatal/lingual) following application of a plaque disclosing agent. Scores will be assigned according to a standardized ordinal scale: score 0 indicates no plaque; score 1 corresponds to a thin film of plaque detectable only with a disclosing agent or upon probing; score 2 indicates a moderate accumulation of soft deposits visible to the naked eye; and score 3 reflects abundant plaque deposits on the gingival margin and adjacent implant surfaces. The PI for each implant will be calculated as the mean of the four site-specific scores. The primary endpoint is the difference in mean PI scores between the trehalose and glycine groups across all timepoints. Outcome assessors will be calibrated and blinded to group allocation.
Time frame: Baseline (T0), 1 month (T1), 3 months (T2), and 6 months (T3)
Change in peri-implant inflammation assessed by Bleeding on Probing (BoP)
Bleeding on Probing (BoP) will be used to assess peri-implant soft tissue inflammation in patients with peri-implant mucositis. BoP will be recorded by gently probing six sites per implant (mesio-buccal, mid-buccal, disto-buccal, mesio-palatal/lingual, mid-palatal/lingual, disto-palatal/lingual) using a standardized periodontal probe. A positive BoP score is assigned if bleeding occurs within 30 seconds after probing. Each site is scored as either 0 (no bleeding) or 1 (bleeding present). The BoP percentage per implant is calculated as the number of bleeding sites divided by the total number of sites examined (×100). The outcome measure will compare the mean BoP percentages between the Trehalose and Glycine groups across all timepoints. Clinical assessments will be performed by calibrated and blinded investigators.
Time frame: Baseline (T0), 1 month (T1), 3 months (T2), and 6 months (T3)
Change in peri-implant probing depth assessed by Probing Pocket Depth (PPD)
Probing Pocket Depth (PPD) will be used to evaluate changes in peri-implant sulcus depth, an indicator of soft tissue inflammation and healing. PPD will be measured using a standardized millimeter-graded periodontal probe at six sites per implant: mesio-buccal, mid-buccal, disto-buccal, mesio-palatal/lingual, mid-palatal/lingual, and disto-palatal/lingual. The probe is inserted parallel to the long axis of the implant, and the distance from the gingival margin to the base of the sulcus is recorded in millimeters. The mean PPD per implant will be calculated and compared between the Trehalose and Glycine groups at all study timepoints. Measurements will be performed by calibrated and blinded examiners.
Time frame: Baseline (T0), 1 month (T1), 3 months (T2), and 6 months (T3)
Change in gingival bleeding severity assessed by Bleeding Score (BS)
The Bleeding Score (BS) quantifies the severity of bleeding upon probing in peri-implant tissues. It will be recorded at each implant site showing a positive BoP response, based on the following scale: score 1 indicates minimal bleeding (isolated point), score 2 indicates moderate bleeding (line or triangle of blood), and score 3 indicates profuse bleeding (immediate blood flow covering the implant surface). The BS per implant is calculated as the mean of all site-specific scores. The outcome compares mean BS values between the Trehalose and Glycine groups at each timepoint. All probing will be performed by calibrated, blinded clinicians using gentle pressure.
Time frame: Baseline (T0), 1 month (T1), 3 months (T2), and 6 months (T3)
Changes in implant surface morphology assessed by Scanning Electron Microscopy (SEM)
Scanning Electron Microscopy (SEM) will be used to evaluate potential morphological changes on implant surfaces after treatment with trehalose or glycine powder. In vitro tests will be conducted using standard titanium dental implant fixtures treated separately with either trehalose or glycine powder under identical air-polishing protocols. After treatment, implants will be cleaned, fixed, and analyzed using a high-resolution desktop SEM system. Surface alterations such as scratches, loss of microstructure, or contaminant residues will be assessed qualitatively and compared descriptively between groups.
Time frame: 6 months (T3)
Plan to share: No — Data will be available upon motivated request to the corresponding authors.
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Jun 2026, 9 months after the start.
Of 67 non-industry interventional studies with no phase under Mucositis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 26. This study's planned 9 months is below that.
Counting every sponsor, half of 70 studies reached it within 12 months; a quarter within 6 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.